TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12490966

Group type: EXPERIMENTAL
Intervention: Azimilide with isoproterenol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 13
Study: 9585236

Group type: EXPERIMENTAL
Intervention: Antigen delivered in a transgenic potato
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injected antigen from transgenic plants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant tissues fed to mice
Number of subjects: 0
Study: 7562029

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy in group A (moderate pain)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy in group B (severe pain)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Automated percutaneous discectomy
Number of subjects: 200
Study: 2635228

Group type: EXPERIMENTAL
Intervention: Warm imagery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cold imagery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Neutral imagery
Number of subjects: 32

Group type: COMPARATOR
Intervention: No-imagery
Number of subjects: 32
Study: 788732

Group type: EXPERIMENTAL
Intervention: Pralidoxime mesylate (P2S) 750 mg and atropine sulphate 2.0 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pralidoxime mesylate (P2S) alone
Number of subjects: 44
Study: 30061531

Group type: EXPERIMENTAL
Intervention: Experimental condition (stimulation with the developed device)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control condition (stimulation with static non‐interoceptive pressure)
Number of subjects: 13
Study: 27093162

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 160
Study: 25213055

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22907440

Group type: EXPERIMENTAL
Intervention: Prokinetic with split-dose PEG (100 mg itopride administered twice with each split-dose of PEG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-dose PEG alone
Number of subjects: 0
Study: 20471311

Group type: EXPERIMENTAL
Intervention: IdentEvent™ seizure detection system
Number of subjects: 102

Group type: COMPARATOR
Intervention: Persyst's Reveal® (three parameter settings)
Number of subjects: 102
Study: 18767583

Group type: EXPERIMENTAL
Intervention: Acupuncture at corresponding channel points (Gallbladder Channel and Bladder Channel)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Routine acupuncture at routinely selected acupoints
Number of subjects: 165
Study: 15981676

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (n=26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy (n=11)
Number of subjects: 51
Study: 12921618

Group type: EXPERIMENTAL
Intervention: Modified anti-shock programme (urine output maintained at 100 ml/h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional resuscitation formula (urine output maintained at 40 ml/h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 12575374

Group type: EXPERIMENTAL
Intervention: New Zhengtian Pill (NZTP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fuguiqin Capsule (Control)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy persons (comparison group)
Number of subjects: 68
Study: 9364538

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 for 1 hour every 3 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mitomycin (12 mg/m2 every 6 weeks) plus Vinblastine (6 mg/m2 every 3 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mitomycin/Vinblastine
Number of subjects: 200
Study: 1540762

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 3892293

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (daily for eight days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin and Diethylcarbamazine
Number of subjects: 30
Study: 31638970

Group type: EXPERIMENTAL
Intervention: Surgical treatment and radiation for Oral Cancer
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Self-treatment prior to specialist consultation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Treatment initiation after confirmed diagnosis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Financial expenditure on treatment
Number of subjects: 14
Study: 28891153

Group type: EXPERIMENTAL
Intervention: Off-site depression collaborative care (delivered by depression care manager, pharmacist, and psychiatrist)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Off-site depression collaborative care
Number of subjects: 292
Study: 25802933

Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthosis (DEFO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 24247022

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 22453581

Group type: EXPERIMENTAL
Intervention: clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 458

Group type: COMPARATOR
Intervention: individual active ingredients and vehicle
Number of subjects: 458

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 458
Study: 20214078

Group type: EXPERIMENTAL
Intervention: Needle retention time in acupuncture treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17323403

Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Diclofenac with PPI
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: PPI effect without stratification
Number of subjects: 979
Study: 16249145

Group type: EXPERIMENTAL
Intervention: Topical caffeine 10%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11878517

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 20
Study: 9508672

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers)
Number of subjects: 21
Study: 7943519

Group type: EXPERIMENTAL
Intervention: Ligament augmentation device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendons alone (Control)
Number of subjects: 60
Study: 2852389

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 micrograms twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2024740

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 3 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 20
Study: 780038

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 0
Study: 29746385

Group type: EXPERIMENTAL
Intervention: High-volume running (HVR - twelve sprints per over)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-volume running (MVR - six sprints per over)
Number of subjects: 20
Study: 27780479

Group type: EXPERIMENTAL
Intervention: Air Barrier System
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine operating room atmospheric conditions (Control)
Number of subjects: 300
Study: 25827659

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23549644

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5372
Study: 22352084

Group type: EXPERIMENTAL
Intervention: Community engagement kickoff conference
Number of subjects: 187
Study: 19346952

Group type: EXPERIMENTAL
Intervention: Miglustat (200 mg TID)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No miglustat treatment (Control)
Number of subjects: 30
Study: 16801588

Group type: EXPERIMENTAL
Intervention: Random HbA1c (A1C)
Number of subjects: 2820

Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 2820
Study: 15338068

Group type: EXPERIMENTAL
Intervention: 5 mg/kg cimetidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 1)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg ranitidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 2)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine p.o. + 0.1 mg/kg dimetindene i.v. 1 to 2 h before induction of anaesthesia (Group 3)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: 20 ml saline solution i.v. 20 min before induction of anaesthesia (Control Group 4)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (n = 443)
Number of subjects: 1149
Study: 11206660

Group type: EXPERIMENTAL
Intervention: Vocational interventions for persons who were unemployed
Number of subjects: 218
Study: 9039510

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Oxandrolone (Ox) 0.0625 mg/kg/day po
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Testosterone (T) 5 mg i.m. every 14 days
Number of subjects: 20
Study: 7942486

Group type: EXPERIMENTAL
Intervention: Flow-convergence method for measuring effective regurgitant orifice area (ROA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flow-convergence method for measuring effective ROA
Number of subjects: 45
Study: 3066966

Group type: EXPERIMENTAL
Intervention: isoptin (10 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: obsidan (5 mg)
Number of subjects: 35
Study: 30143383

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 2638

Group type: COMPARATOR
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 2638
Study: 28885034

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD) with miniscrew anchorage
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study: 25790670

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC) - 3 pills each time, 3 times a day for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: SASP (sulfasalazine) - 4 tablets each time, twice a day for 3 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: XFC
Number of subjects: 120
Study: 23327229

Group type: COMPARATOR
Intervention: Adper Single Bond Plus
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adper Scotchbond SE
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Adper Easy Bond
Number of subjects: 156
Study: 21612139

Group type: EXPERIMENTAL
Intervention: 10 mL/kg of Ringer's lactate (RL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15 mL/kg of Ringer's lactate (RL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mL/kg of Ringer's lactate (RL)
Number of subjects: 90
Study: 19422345

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir (for 21 days) followed by once daily valganciclovir until day 49
Number of subjects: 321

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (twice daily for 21 days)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Both treatments (valganciclovir and ganciclovir)
Number of subjects: 321
Study: 16949694

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with 64 Gy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (CFRT) with 74 Gy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: D90 > or = 50 Gy to the penile bulb
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Correlation of dose to the penile bulb and crura
Number of subjects: 51
Study: 15719855

Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine (10 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 11564483

Group type: EXPERIMENTAL
Intervention: levodopa 100 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 9643623

Group type: EXPERIMENTAL
Intervention: Verapamil SR 180 mg and trandolapril 0.5 mg
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Verapamil SR 180 mg and trandolapril 1.0 mg
Number of subjects: 456

Group type: COMPARATOR
Intervention: Verapamil SR (120, 180 mg) and trandolapril (0.5, 1.0, 2.0 mg)
Number of subjects: 456
Study: 7941937

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 40
Study: 3062528

Group type: EXPERIMENTAL
Intervention: Topical 0.5% levobunolol before unilateral Nd:YAG laser posterior capsulotomy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Topical 0.5% levobunolol after unilateral ECCE
Number of subjects: 83
Study: 31319747

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2% lidocaine without a vasoconstrictor
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both lidocaine with and without epinephrine
Number of subjects: 28
Study: 27642762

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Screen time intervention
Number of subjects: 202
Study: 26053604

Group type: EXPERIMENTAL
Intervention: Viscoelastic foam 1 (n = 53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Viscoelastic foam 2 (n = 52)
Number of subjects: 105
Study: 23769023

Group type: EXPERIMENTAL
Intervention: HMP through hepatic artery (HA) alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HMP through HA and portal vein (PV)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HMP through PV alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: ≥8 hours cold storage (CS)
Number of subjects: 16
Study: 21577010

Group type: EXPERIMENTAL
Intervention: 100 mg opipramol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 150 mg opipramol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 19736554

Group type: EXPERIMENTAL
Intervention: EPIPOI‐1 (basic information on overweight and health, screening for overweight)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EPIPOI‐2 (education on nutrition, physical activity, and sedentary behaviors)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (non-intervention kindergartens)
Number of subjects: 79
Study: 16490494

Group type: EXPERIMENTAL
Intervention: Three-piece acrylic IOL
Number of subjects: 105

Group type: COMPARATOR
Intervention: Three-piece silicone IOL
Number of subjects: 105

Group type: COMPARATOR
Intervention: One-piece acrylic IOL
Number of subjects: 105
Study: 15799913

Group type: EXPERIMENTAL
Intervention: Shelhigh prosthesis
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Double-valve replacement (both Shelhigh)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Aortic Shelhigh prosthesis with concomitant mitral valve reconstruction
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Homografts
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Mitral valve reconstruction
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement due to severe damage
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Other types of surgery
Number of subjects: 327

Group type: COMPARATOR
Intervention: Homografts vs Shelhigh stentless prosthesis
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Risk factors for mortality
Number of subjects: 327
Study: 11273498

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy, 5 million units (MU) subcutaneously thrice a week for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo therapy (Control)
Number of subjects: 54
Study: 9109139

Group type: EXPERIMENTAL
Intervention: Amoxicillin once daily (qd)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Amoxicillin twice daily (bid)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: COMPARATOR
Intervention: Amoxicillin (qd or bid)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Amoxicillin (qd) vs. Amoxicillin (bid)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Amoxicillin (qd or bid) vs. Placebo
Number of subjects: 158
Study: 1394811

Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin (ADM) + 200 mg cytosine arabinoside (CA) in 30 ml physiological saline (group A)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 10 mg peplomycin (PEP) + 200 mg CA in 30 ml physiological saline (group B)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 2 mg neocarzinostatin (NCS) + 200 mg CA in 30 ml physiological saline (group C)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (group D)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 300 mg/day UFT (group E)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 200 mg 5‐fluorouracil (5‐FU)/day (group F)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 20 mg ADM + 200 mg CA in 30 ml physiological saline + 30 mg ubenimex/day (group G)
Number of subjects: 314

Group type: COMPARATOR
Intervention: No oral drug (group H)
Number of subjects: 314
Study: 3840612

Group type: EXPERIMENTAL
Intervention: Bromopride (20 mg) administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo administered via i.v. injection half an hour before chemotherapy and at 3 1/2 and 7 1/2 hours following chemotherapy.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bromopride (20 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 29283904

Group type: EXPERIMENTAL
Intervention: Full‐spectrum colonoscopy with the Fuse system (330 degrees)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard forward‐viewing colonoscopy (170 degrees)
Number of subjects: 249
Study: 30095608

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 26
Study: 25256380

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training (BF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 12
Study: 24011750

Group type: EXPERIMENTAL
Intervention: Educational intervention (video and written information)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 132
Study: 22368996

Group type: EXPERIMENTAL
Intervention: Kinesiology treatment for a period of 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 19373423

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole
Number of subjects: 821

Group type: COMPARATOR
Intervention: Control (placebo, H2 receptor antagonist, or somatostatin)
Number of subjects: 821
Study: 17499091

Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesives (G-Bond, iBond, Clearfil S(3))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesives (Clearfil SE, Optibond Solo Plus Self-Etch)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total-etch adhesive (Prime & Bond NT)
Number of subjects: 24
Study: 15848824

Group type: EXPERIMENTAL
Intervention: web-based community simulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: traditional assignment
Number of subjects: 14
Study: 11590678

Group type: EXPERIMENTAL
Intervention: Beta-radiation therapy ((188)Re-MAG(3))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (rotational atherectomy and balloon angioplasty)
Number of subjects: 50
Study: 9833601

Group type: EXPERIMENTAL
Intervention: Acipimox (500 or 750 mg daily for 12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 18
Study: 9695160

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone over eight weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1677821

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.10 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.09 mg/kg)
Number of subjects: 48
Study: 6307135

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone therapy continued after discharge
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftriaxone therapy
Number of subjects: 100
Study: 30622317

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Irbesartan 150 mg
Number of subjects: 38
Study: 30128705

Group type: EXPERIMENTAL
Intervention: Talcom 75 mg od + aspirin 100 mg od
Number of subjects: 248

Group type: COMPARATOR
Intervention: Plavix 75 mg od + aspirin 100 mg od
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Talcom
Number of subjects: 248

Group type: COMPARATOR
Intervention: Plavix
Number of subjects: 248
Study: 27423688

Group type: EXPERIMENTAL
Intervention: Subgroup analysis reported in RCTs
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Appropriate methods for subgroup analysis
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Subgroup analysis reporting by year
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Use of appropriate methods over time
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Predictors of reporting subgroup analysis
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Use of appropriate methods in industry-funded trials
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Examination of subgroup effects using multivariable risk index
Number of subjects: 437